Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 14/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421609 | 0.92 | GCK (0.43) | GCKPARP1HRH3KCNH2ABL1 | |
| SCHEMBL425093 | 0.91 | GCK (0.42) | GCKPARP1HRH3KCNH2ABL1 | |
| SCHEMBL424425 | 0.86 | GCK (0.42) | GCKPARP1KCNH2BTKABL1 | |
| SCHEMBL420620 | 0.86 | GCK (0.52) | GCKKCNH2ABL1 | |
| SCHEMBL424679 | 0.86 | GCK (0.40) | GCKHRH3KCNH2 | |
| SCHEMBL423373 | 0.85 | GCK (0.44) | GCKKCNH2 | |
| SCHEMBL426280 | 0.84 | GCK (0.43) | GCKKCNH2ABL1 | |
| SCHEMBL424292 | 0.83 | GCK (0.43) | GCKKCNH2ABL1 | |
| SCHEMBL9071140 | 0.81 | GCK (0.48) | GCK | |
| SCHEMBL423075 | 0.81 | GCK (0.48) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2239253-B1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-8415359-B2 | Phenylpyrrole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-09 | — | — | US | disclosed |
| US-8415359-B2 | Phenylpyrrole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20120022075-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20120022075-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-26 | — | — | US | disclosed |
| US-8017610-B2 | Phenylpyrrole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-09-13 | — | — | US | disclosed |
| US-8017610-B2 | Phenylpyrrole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20110003787-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
| US-20110003787-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2239253-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-10-13 | — | — | EP | disclosed |
| EP-2239253-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009099080-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003787-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | GCKR, GCK, SLC5A1 | GCK 2/4885PARP1 2845/4885HRH3 1823/4885 |
| US-20120022075-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | GCKR, GCK, SLC5A1 | GCK 2/4885PARP1 2845/4885HRH3 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.